Sorafenib is the classic first-line unresectable HCC drug (13, 59), selectively inducing apoptosis via Bcl-2/caspase-3 while inhibiting normal liver cell cycle (13). This evidence concerns the gene BCL2 and hepatocellular carcinoma.